Parkinson's News Today: Treatment via pump better at controlling symptoms
UC's Espay U.S. principal investigator of international trial
New trial results found a drug delivered continuously through a pump was more effective at controlling symptoms of Parkinson's disease without causing dyskinesia. Dyskinesia refers to involuntary and uncontrolled movements of the limbs, head or whole body that are common in Parkinson's disease patients and associated with long-term use of a Parkinson's drug called levodopa.
The University of Cincinnati's Alberto Espay, MD, was the U.S. principal investigator for the trial that tested the effectiveness of a drug called ND0612. Similarly to an insulin pump for people with diabetes, a pump delivers the liquid drug under the skin over 24 hours.
Over three months, the trial found patients receiving ND0612 had approximately 1.73 more hours of daily "on time," or time when Parkinson's symptoms do not interfere with daily activities, compared to patients who took the drug's oral formulation called LC/DC.
"With these positive results for the primary endpoint [goal] and four secondary endpoints, ND0612 has confirmed its potential as an effective treatment strategy for Parkinson’s disease patients with motor fluctuations, despite optimization of oral therapies,” Espay, director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute and a UC Health physician, told Parkinson's News Today.
"Continuous subcutaneous LD/CD treatment shows promise to change the treatment paradigm and transform the lives of patients with Parkinson’s disease,” Espay continued.
Read the Parkinson's News Today article.
Featured photo at top of Dr. Espay. Photo/University of Cincinnati.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.